Eight in 10 Infants Received RSV Protection in the 2023 to 2024 Season
WEDNESDAY, Jan. 8, 2025 -- Eight in 10 infants received respiratory syncytial virus (RSV) protection during the 2023 to 2024 season, according to a research letter published online Jan. 8 in JAMA Network Open.
Karen B. Jacobson, M.D., M.P.H., from Kaiser Permanente Northern California in Oakland, and colleagues investigated uptake of RSVpreF among pregnant women at 32 to 36 weeks of gestation and nirsevimab among infants aged younger than 8 months, as well as sociodemographic factors associated with uptake within the early period of availability. The analysis included electronic medical record data among 17,251 infants born to mothers aged 15 to 49 years in a single health system between Oct. 17, 2023 (when nirsevimab became available; RSVpreF became available October 25), and March 31, 2024.
The researchers found that 33.9 percent of infants were exposed to only the maternal RSVpreF vaccine, at a median gestational age of 34.0 weeks, while 40.9 percent of infants received only nirsevimab (median age, 4 days). Only 2.7 percent of infants were exposed to both maternal RSVpreF and nirsevimab, and of these, 31.1 percent were born preterm and 24.1 percent were admitted to the neonatal intensive care unit. Infants of mothers younger than 25 years were less likely than infants of mothers 35 years and older to receive only RSVpreF (26.4 versus 37.9 percent), but thy were more likely to receive only nirsevimab (44.2 versus 40.1 percent). Infants of Asian mothers had the highest exposure to RSVpreF and/or nirsevimab (86.7 percent), while infants of Black mothers had the lowest exposure (70.2 percent).
"The availability of two different RSV protection methods in sufficient supply may have contributed to an increased proportion of infants protected against RSV, which may help mitigate disparities," the authors write.
Several authors disclosed ties to pharmaceutical companies, including Pfizer, which manufactures the RSVpreF vaccine, and Sanofi, which manufactures nirsevimab.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Read this next
Influenza-Linked Hospitalization Rate High in 2024 to 2025 Flu Season
WEDNESDAY, Sept. 17, 2025 -- The cumulative influenza-associated hospitalization rate for the 2024 to 2025 season surpassed all end-of-season rates during the period beginning...
RSV Vaccine Prevents RSV-Linked Hospitalization Among Older Adults Over Two Seasons
FRIDAY, Sept. 12, 2025 -- The respiratory syncytial virus (RSV) vaccine reduces RSV-associated hospitalization among older adults over two seasons, according to a study published...
Infants Without Comorbidities Also at Risk for Severe RSV Infection
THURSDAY, Sept. 11, 2025 -- Comorbidities are seen less often in severe respiratory syncytial virus (RSV) infection in infants younger than 3 months compared with older children...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.